CN1065767C - Oral liquor of fermented cordyceps hypha - Google Patents
Oral liquor of fermented cordyceps hypha Download PDFInfo
- Publication number
- CN1065767C CN1065767C CN93104720A CN93104720A CN1065767C CN 1065767 C CN1065767 C CN 1065767C CN 93104720 A CN93104720 A CN 93104720A CN 93104720 A CN93104720 A CN 93104720A CN 1065767 C CN1065767 C CN 1065767C
- Authority
- CN
- China
- Prior art keywords
- oral liquor
- mycelia
- fermented
- fermented cordyceps
- cordyceps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to an oral liquor of fermented cordyceps mycelia, which is prepared by the way that the new species of paecilomyces sinensis are fermented to obtain dry mycelia, and the dry mycelia are processed by decoction extracting, filtering, concentrating, filling and sterilizing. The concentration of the oral liquor is from 20 to 70%, and the specific gravity of quality inspection is greater than or equal to 1.05. The oral liquor contains at least 12% of solid, at least 0.05% of uridine, at least 0.02% of uracil, at least 0.04% of adenosine, 0.004% of adenine and at least 3% of mannitol. The oral liquor has good treating effects on chronic hepatitis B, acquired immune deficiency syndrome, and the survival time prolonging of the allotransplantation of the variant organs of a human body.
Description
The present invention relates to a kind of application of Cordyceps, specifically the peacilomyce hepiahi novel species Paecilomyces HepiaiChen et Dai.sp.nev. that separation and Culture obtains from the fresh Cordyceps is as the application of immunomodulator.
Cordyceps is China's rare Chinese medicine, main product in Sichuan, ground such as Yunnan, Qinghai, Tibet, the sweet temperature of property, lung benefiting kidney, mend marrow, hemostasis and phlegm, cure mainly diseases such as cough due to consumptive disease, sexual impotence, soreness of waist and knee joint.In recent years studies have shown that Cordyceps all has certain effect to aspects such as cardiovascular system, central nervous system, body's immunity, respiratory system, hemopoietic system, endocrine, emergency reactions, also have antiinflammatory, resisting pathogenic microbes, antitumor action simultaneously, can treat multiple disease clinically, stand high in reputation in the international market in medical treatment.Because natural cordyceps is subjected to the restriction of natural conditions, extremely to excavate in addition, output is limited, does not satisfy domestic and international growing needs, has become rare treasure, costs an arm and a leg.In order to solve the medicine source problem, carry out the artificial separation and fermentation of Cordyceps and cultivate mycelium, replacing natural cordyceps to prepare medicine is a kind of effective method.
The object of the present invention is to provide a kind of peacilomyce hepiahi novel species, except that known indications, also can be used for treating disease such as anti-allogeneic rejection in chronic hepatitis B, acquired immune deficiency syndrome (AIDS), hypoimmunity, the organ transplantation.
The objective of the invention is to realize by following scheme.
Peacilomyce hepiahi novel species Paecilomyces Hepiai Chen etDai.sp.nev. separation and Culture from the fresh Cordyceps obtains, after submerged fermentation obtains dried mycelia, boil carry, concentrate, fill, sterilization and pure Chinese medicine oral liquid.Concrete steps are as follows:
1. the Cordyceps preparation of dried mycelia of fermenting.With fresh Cordyceps washing and sterilizing, section, put culture purified on the culture medium, pure culture is inserted Fructus Solani melongenae bottle slant culture, culture medium prescription is a glucose 1～3%, peptone 0.5～2%, Pupa bombycis 0.5～2%, milk powder 0.5～2%, Na HPO 0.05～0.15%, K HOP 0.1～0.2%; Agar 2～4%, water 85～95%.Again through one-level, secondary, three grade fermemtation makes the dried mycelia of fermentation.
2. the preparation of oral liquid.Get the Cordyceps dried mycelia of fermenting and add 8～10 times in water, boil twice totally, each 1.5～2 hours, through 1500～2500 rev/mins of centrifugations, 30 minutes, get the supernatant activated carbon filtration, be evaporated to every milliliter again and contain mycelia 0.2～0.7 gram, pH4.5～5.5,10 milliliters/bottle of packing loading amounts, oral liquid concentration is 20～70%, circulation steam sterilization 30 minutes.Quality testing pH4.5～5.5, proportion contain solids more than or equal to 12% more than or equal to 1.05, the assay uridnine is more than or equal to 0.05%, and uracil is more than or equal to 0.02%, and adenosine is more than or equal to 0.04%, adenine is more than or equal to 0.004%, and mannitol is more than or equal to 3%.
Advantage of the present invention is: 1. use the dried mycelium of Chinese caterpillar fungus fermentation to make crude drug, low price has solved natural cs medicine source deficiency.2. select oral liquid formulation for use, taking convenience easily absorbs the bioavailability height.3. through acute toxicity, long term toxicity, toxicological experiments such as mutagenesis, genotoxicity proof is without any side effects, safe and reliable.4. pharmacological action is extensive.The experiment proved that this oral liquid is an immunomodulator, immune enhancing function is arranged during low dosage, immunosuppressive action is arranged during high dose.It can prolong allograft of skin mice and rat allosome heart transplantation survival period, has anti-repulsive interaction.Anti-tumor experiment proof has the effect of the cell mutation of inhibition, is 78.3% to the suppression ratio of mouse skin carcinogenesis, and medullary cell is had stimulation.Anti-platelet aggregation effect and anti thrombotic action have been experimental results show that through anti-platelet aggregation.After the animal of hepatitis b virus infection was taken medicine, DNA had remarkable inhibitory action to its serum-virus, and the mice toxic hepatitis to carbon tetrachloride poisoning causes can reduce gpt activity in the serum.The rat body weight gain there is facilitation, can improves the ability that animal conforms.Rat acute arthritis, immune plyability arthritis animal all there is remarkable effect.5. clinical efficacy is extensive, and has one's own knack.Prove through clinical research, but the blood fat reducing of this medicine, reduce lipid peroxide contents, prevent and treat arteriosclerosis, increase cardiac muscle and blood supply in brain, anti-arrhythmia.The treatment nephrotic syndrome of children, rheumatoid arthritis, nephritis etc.Weak, liver pain, poor appetite, the symptom of being afraid of cold of particularly outstanding is this oral liquid can make chronic hepatitis B patient are obviously improved, and the hepatitis B serum-virus is learned index hepatitis B E antigen HBeAg, and hepatitis b virus hbv has the effect of necessarily turning out cloudy.E antigen negative conversion rate is 40～50%, and titre descends 20%, and improvement rate is 70%, and can anti-hepatic fibrosis.The anti-AIDS effect is obvious, and is on probation through Tanzania HIV (human immunodeficiency virus) infection patient, and symptom takes a turn for the better, and effective percentage is 29.3%, and can prolong human body allosome organ transplantation survival period.
Embodiment:
Get the dried mycelia 500g of Chinese caterpillar fungus fermentation, 8 times of adding distil waters decoct twice, collecting decoction was through 2200 rev/mins of centrifugations, 30 minutes, get supernatant ripple activated carbon filtration, be evaporated to every milliliter and contain mycelia 0.5 gram, pH value transfers to 5.0, totally 1000 milliliters, 10 milliliters/bottle of embeddings, totally 100 bottles, yellowish-brown is to the pale red clear liquid, special hide arranged slightly, little hardship.Quality testing proportion is 1.05, contains solids 12.5,10 milliliters of loading amounts, and uridnine content is 0.06%, and uracil content is 0.025%, and adenosine content is 0.05%, adenine 0.0045%, mannitol is 3.5%, clinical application effect is good.
Claims (3)
1. the application of peacilomyce hepiahi novel species in the medicine of preparation treatment acquired immune deficiency syndrome (AIDS).
2. the application of peacilomyce hepiahi novel species in preparation treatment hepatitis B, the early stage fibrosis medicine of liver.
3. the application of peacilomyce hepiahi novel species in preparation organ transplantation immunity inhibitor medicaments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93104720A CN1065767C (en) | 1993-05-10 | 1993-05-10 | Oral liquor of fermented cordyceps hypha |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93104720A CN1065767C (en) | 1993-05-10 | 1993-05-10 | Oral liquor of fermented cordyceps hypha |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1081895A CN1081895A (en) | 1994-02-16 |
| CN1065767C true CN1065767C (en) | 2001-05-16 |
Family
ID=4985316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93104720A Expired - Fee Related CN1065767C (en) | 1993-05-10 | 1993-05-10 | Oral liquor of fermented cordyceps hypha |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1065767C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048404C (en) * | 1994-07-28 | 2000-01-19 | 杨思齐 | Oral liquid for treatment of B-hepatitis by use of termite as main raw material |
| CN1063089C (en) * | 1996-06-18 | 2001-03-14 | 张景元 | Log mycelium decaction liquor and its preparation method |
| CN101560268B (en) * | 2009-05-31 | 2013-11-20 | 江西济民可信集团有限公司 | Cs-4 fermentation mycelium polysaccharide and preparation method and applications thereof |
| CN101869337A (en) * | 2010-05-11 | 2010-10-27 | 河南省申氏菇业有限公司 | Pleurotus ferulae and cordyceps mycelium oral solution and production method thereof |
| CN101991614A (en) * | 2010-09-13 | 2011-03-30 | 吴赣英 | Compound fermented cordyceps sinensis powder (paecilomyces hepiali Cs-4 bacterial powder) combined medicine and preparation thereof |
| EP2913055A4 (en) | 2013-12-31 | 2015-12-23 | Zhonglin Wang | Pharmaceutical composition for treating acquired immune deficiency syndrome and method for preparing same |
| CN104096111A (en) * | 2014-07-23 | 2014-10-15 | 深圳德沃时尚投资有限公司 | Blood sugar regulating and immune regulating tripartite cordyceps sinensis oral liquid |
-
1993
- 1993-05-10 CN CN93104720A patent/CN1065767C/en not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| 《中国泌尿外科杂志》1991,12(5) 1991.5.30 管德林等，人工培养冬虫夏草(Q80)在肾移植中的临床研究 * |
| 《北京农业大学学报》1989,15(2) 1989.2.28 戴如琴等，蝙蝠蛾拟青霉新种的研究 * |
| 《北京农业大学学报》1989,15(2) 1989.2.28 戴如琴等，蝙蝠蛾拟青霉新种的研究;《山西中医》1989,5(6) 1989.6.30 胡世昭等，至灵胶囊治疗慢性乙肝的疗效观察;《实用中西医结合杂志》1991,4(4) 1991.4.30 张夏，治疗艾滋病有关中草药选解;《中国泌尿外科杂志》1991,12(5) 1991.5.30 管德林等，人工培养冬虫夏草(Q80)在肾移植中的临床研究 * |
| 《实用中西医结合杂志》1991,4(4) 1991.4.30 张夏，治疗艾滋病有关中草药选解 * |
| 《山西中医》1989,5(6) 1989.6.30 胡世昭等，至灵胶囊治疗慢性乙肝的疗效观察 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1081895A (en) | 1994-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN101569690B (en) | Preparation method for compound plant polypeptide | |
| CN104382164A (en) | Beverage prepared from lucid ganoderma and black tea fungus | |
| CN102669348B (en) | Nutrition food of heart nourishing tea granule for nourishing heart | |
| KR100414140B1 (en) | Health composition | |
| CN106214989A (en) | A kind of defying age, the deer's blood health-care medicated wine improving memory and preparation method thereof | |
| CN104147383A (en) | Antitumor composition and preparation method thereof | |
| CN1065767C (en) | Oral liquor of fermented cordyceps hypha | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| US5759543A (en) | Application of a cell culture of a fusarium fungus strain producer for medical uses | |
| CN115137069A (en) | Lactobacillus delbrueckii subspecies bulgaricus SF-L-18 fermented product and preparation method and application thereof | |
| CN110656151A (en) | Method for improving kidney-tonifying and yang-strengthening effects of sea cucumber | |
| CN109452634A (en) | Mycosymbiosis fermentation blood sugar-reducing Moringa and preparation method thereof | |
| CN105288226A (en) | Kidney-invigorating and yang-strengthening composition and preparation method thereof | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN106616945A (en) | Postbiotic and probiotic compound taking cordyceps adenosine as substrate and preparation method of postbiotic and probiotic compound | |
| JP4000946B2 (en) | New production method of cordyceps and the obtained cordyceps and its use | |
| CN114869953B (en) | Composition for resisting fatigue and enhancing immunity and treating rheumatism and preparation method thereof | |
| CN105233250B (en) | A kind of composite biological agent for being used to treat encephalopathy | |
| CN113332327A (en) | Application of American ginseng and astragalus preparation in preparing product for improving immunity | |
| Alexander et al. | The role of fecal thiamine and cocarboxylase in human nutrition | |
| CN105941768A (en) | Camellia chrysantha tuyama containing ganoderma lucidum hyphae | |
| CN110754662B (en) | Yellow blood silkworm cordyceps militaris chicken essence electuary suitable for people prone to fatigue and preparation method thereof | |
| CN1110546C (en) | Cordyceps and production and use thereof | |
| CN1033939A (en) | Preparation of immunostimulant oral liquid and extracting method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |